Skip to main content

Market Overview

Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

Share:
Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
  • Aptose Biosciences Inc (NASDAQ: APTOhighlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies.
  • In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mg/m2 over multiple cycles supporting continued dose escalation.
  • APTO-253 monomer rapidly transformed to and co-existed with the Fe(253)3 conjugate in peripheral blood.
  • Serum levels of APTO-253 and the Fe(253)3 conjugate were dose-proportional, with significantly higher Fe(253)3 conjugate concentrations than monomer.
  • In Relapsed or Refractory B-Cell Malignancies, the anti-tumor activity observed in multiple patients, including follicular lymphoma (FL), Waldenstrom’s (WM), Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • Tumor reduction in a patient with follicular lymphoma (FL) upon dose escalation from 450 mg to 600 mg.
  • IgM reduction in a patient with Waldenstrom’s (WM) at 750mg dose.
  • Dose escalation well-tolerated from 150 – 600 mg twice daily over multiple cycles.
  • One apparent dose-limiting toxicity of hypertension led to expansion at 750 mg – upon further review appears unlikely related.
  • Currently treating patients with B-cell malignancies at 750 mg BID in cohort 5; continued dose escalation planned.
  • See the slide presentation here.
  • Price Action: APTO shares are down 31.5% at $3.79 during the market session on the last check Friday.
 

Related Articles (APTO)

View Comments and Join the Discussion!

Posted-In: Briefs leukemiaBiotech News Penny Stocks Health Care Small Cap General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com